**Supplemental Table 1.** Baseline clinical and pathological characteristics of 32 patients with advanced PanNET treated with TEM, matched with 32 patients with advanced PanNET treated with TEM-CAP. Matching was performed on the propensity score, which aimed to predict the individual probability to receive TEM-CAP rather than TEM, depending on baseline characteristics.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **TEM**  **N=32** | **TEM-CAP**  **N=32** | **p-value** | **Standardized difference** |
| **Male gender, n (%)** | 16 (50) | 20 (62.5) | 0.31 | 0.25 |
| **Age (years), mean ± std** | 60.5 ± 11.9 | 61.4 ± 9.0 | 0.48 | 0.09 |
| **Hormonal syndrome, n (%)** | 8 (25) | 10 (31.3) | 0.58 | 0.14 |
| **Ki67 index (%), mean ± std** | 8.3 ± 6.4 | 8.3 ± 7.4 | 0.66 | 0.01 |
| **Tumor grade, n (%)** |  |  | 0.35 | 0.24 |
| G1 | 5 (15.6) | 8 (25.0) |  |  |
| G2 | 27 (84.4) | 24 (75) |  |  |
| **WHO performance status, n (%)** |  |  | 0.19 | 0.33 |
| PS-0 | 18 (56.3) | 23 (71.9) |  |  |
| PS-1 or PS-2 | 14 (43.7) | 9 (28.1) |  |  |
| **Tumor stage, n (%)** |  |  | 0.61 | 0.12 |
| Locally advanced or liver metastases only | 19 (59.4) | 17 (53.1) |  |  |
| Extra-hepatic metastases | 13 (46.6) | 15 (46.9) |  |  |
| **Delay from diagnosis (months), mean ± std** | 51.2 ± 40.3 | 50.0 ± 42 | 0.87 | -0.08 |
| **Previous treatments, n (%)** |  |  |  |  |
| Primary tumor surgery | 17 (53.1) | 24 (75) | 0.07 | 0.47 |
| Chemotherapy | 12 (37.5) | 10 (31.3) | 0.60 | -0.13 |
| Targeted therapy | 9 (28.1) | 9 (28.1) | 1.0 | 0.00 |
| CEL | 6 (18.8) | 4 (12.5) | 0.49 | -0.17 |
| RVI | 2 (6.3) | 1 (3.1) | 1.0 | -0.15 |
| Somatostatin analogs | 16 (50) | 15 (46.9) | 0.80 | -0.06 |
| **Number of previous lines, mean ± std** | 1.4 ± 1.3 | 1.4 ± 1.4 | 0.91 | 0.00 |
| 0 previous line | 9 (28.1) | 9 (28.1) |  |  |
| ≥ 1 previous line | 23 (71.9) | 23 (71.9) |  |  |